https://ir.acadia-pharm.com/news-re...armaceuticals-and-stoke-therapeutics-announce
– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program
– Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undisclosed neurodevelopmental target
– Combines Stoke’s TANGO research platform with Acadia’s expertise in neurology drug development and commercialization
– Stoke receives a $60 million upfront payment and potential milestone payments of up to $907 million and royalties on future sales
https://ir.acadia-pharm.com/news-releases/news-release-details/ac...
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.10 |
Change
-0.255(2.06%) |
Mkt cap ! $1.545B | |||
| Open | High | Low | Value | Volume |
| $12.20 | $12.20 | $12.02 | $1.099M | 90.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 160 | $12.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.10 | 1042 | 14 |
View Market Depth
| Last trade - 12.42pm 01/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |